Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors : Data from the EuroSpA collaboration

Ørnbjerg, Lykke M. ; Linde, Louise ; Georgiadis, Stylianos ; Rasmussen, Simon H. ; Lindström, Ulf ; Askling, Johan ; Michelsen, Brigitte ; Giuseppe, Daniela Di ; Wallman, Johan K. LU and Pavelka, Karel , et al. (2022) In Seminars in Arthritis and Rheumatism 56.
Abstract

Objectives: In patients with axial spondyloarthritis (axSpA) initiating their first tumor necrosis factor alpha-inhibitor (TNFi), we aimed to identify common baseline predictors of Ankylosing Spondylitis Disease Activity Score (ASDAS-CRP) inactive disease (primary objective) and clinically important improvement (CII) at 6 months, and drug retention at 12-months across 15 European registries. Methods: Baseline demographic and clinical characteristics were collected. Outcomes were investigated per registry and in pooled data using logistic regression analyses on multiply imputed data. Results: The consistency of baseline predictors in individual registries justified pooling the data. In the pooled dataset (n = 21,196), the 6-month rates... (More)

Objectives: In patients with axial spondyloarthritis (axSpA) initiating their first tumor necrosis factor alpha-inhibitor (TNFi), we aimed to identify common baseline predictors of Ankylosing Spondylitis Disease Activity Score (ASDAS-CRP) inactive disease (primary objective) and clinically important improvement (CII) at 6 months, and drug retention at 12-months across 15 European registries. Methods: Baseline demographic and clinical characteristics were collected. Outcomes were investigated per registry and in pooled data using logistic regression analyses on multiply imputed data. Results: The consistency of baseline predictors in individual registries justified pooling the data. In the pooled dataset (n = 21,196), the 6-month rates for ASDAS inactive disease and ASDAS CII were 26% and 51%, and the 12-month drug retention rate 65% in patients with available data (n = 9,845, n = 6,948 and n = 21,196, respectively). Nine common baseline predictors of ASDAS inactive disease, ASDAS CII and 12-month drug retention were identified, and the odds ratios (95%-confidence interval) for ASDAS inactive disease were: age, per year: 0.97 (0.97–0.98), men vs. women: 1.88 (1.60–2.22), current vs. non-smoking: 0.76 (0.63–0.91), HLA-B27 positive vs. negative: 1.51 (1.20–1.91), TNF start year 2015–2018 vs. 2009–2014: 1.24 (1.06–1.45), CRP>10 vs. ≤10 mg/l: 1.49 (1.25–1.77), one unit increase in health assessment questionnaire (HAQ): 0.77 (0.58–1.03), one-millimeter (mm) increase in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) fatigue and spinal pain: 0.99 (0.99–1.00) and 0.99 (0.99–1.99), respectively Conclusion: Common baseline predictors of treatment response and adherence to TNFi could be identified across data from 15 European registries, indicating that they may be universal across different axSpA populations.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Ankylosing spondylitis disease activity score, Axial spondyloarthritis, Predictors, TNF-inhibitors
in
Seminars in Arthritis and Rheumatism
volume
56
article number
152081
publisher
W.B. Saunders
external identifiers
  • pmid:35985172
  • scopus:85135923596
ISSN
0049-0172
DOI
10.1016/j.semarthrit.2022.152081
language
English
LU publication?
yes
id
76c17354-3c65-4128-a799-1470441ed8a1
date added to LUP
2022-10-20 17:05:57
date last changed
2024-04-04 12:52:06
@article{76c17354-3c65-4128-a799-1470441ed8a1,
  abstract     = {{<p>Objectives: In patients with axial spondyloarthritis (axSpA) initiating their first tumor necrosis factor alpha-inhibitor (TNFi), we aimed to identify common baseline predictors of Ankylosing Spondylitis Disease Activity Score (ASDAS-CRP) inactive disease (primary objective) and clinically important improvement (CII) at 6 months, and drug retention at 12-months across 15 European registries. Methods: Baseline demographic and clinical characteristics were collected. Outcomes were investigated per registry and in pooled data using logistic regression analyses on multiply imputed data. Results: The consistency of baseline predictors in individual registries justified pooling the data. In the pooled dataset (n = 21,196), the 6-month rates for ASDAS inactive disease and ASDAS CII were 26% and 51%, and the 12-month drug retention rate 65% in patients with available data (n = 9,845, n = 6,948 and n = 21,196, respectively). Nine common baseline predictors of ASDAS inactive disease, ASDAS CII and 12-month drug retention were identified, and the odds ratios (95%-confidence interval) for ASDAS inactive disease were: age, per year: 0.97 (0.97–0.98), men vs. women: 1.88 (1.60–2.22), current vs. non-smoking: 0.76 (0.63–0.91), HLA-B27 positive vs. negative: 1.51 (1.20–1.91), TNF start year 2015–2018 vs. 2009–2014: 1.24 (1.06–1.45), CRP&gt;10 vs. ≤10 mg/l: 1.49 (1.25–1.77), one unit increase in health assessment questionnaire (HAQ): 0.77 (0.58–1.03), one-millimeter (mm) increase in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) fatigue and spinal pain: 0.99 (0.99–1.00) and 0.99 (0.99–1.99), respectively Conclusion: Common baseline predictors of treatment response and adherence to TNFi could be identified across data from 15 European registries, indicating that they may be universal across different axSpA populations.</p>}},
  author       = {{Ørnbjerg, Lykke M. and Linde, Louise and Georgiadis, Stylianos and Rasmussen, Simon H. and Lindström, Ulf and Askling, Johan and Michelsen, Brigitte and Giuseppe, Daniela Di and Wallman, Johan K. and Pavelka, Karel and Závada, Jakub and Nissen, Michael J. and Jones, Gareth T. and Relas, Heikki and Pirilä, Laura and Tomšič, Matija and Rotar, Ziga and Geirsson, Arni Jon and Gudbjornsson, Bjorn and Kristianslund, Eirik K. and van sder Horst-Bruinsma, Irene and Loft, Anne Gitte and Laas, Karin and Iannone, Florenzo and Corrado, Addolorata and Ciurea, Adrian and Santos, Maria J. and Santos, Helena and Codreanu, Catalin and Akkoc, Nurullah and Gunduz, Ozgul S. and Glintborg, Bente and Østergaard, Mikkel and Hetland, Merete Lund}},
  issn         = {{0049-0172}},
  keywords     = {{Ankylosing spondylitis disease activity score; Axial spondyloarthritis; Predictors; TNF-inhibitors}},
  language     = {{eng}},
  month        = {{10}},
  publisher    = {{W.B. Saunders}},
  series       = {{Seminars in Arthritis and Rheumatism}},
  title        = {{Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors : Data from the EuroSpA collaboration}},
  url          = {{http://dx.doi.org/10.1016/j.semarthrit.2022.152081}},
  doi          = {{10.1016/j.semarthrit.2022.152081}},
  volume       = {{56}},
  year         = {{2022}},
}